Built on extensive experience in LNP delivery, Enorna's tLNP platform delivers research- and GLP-grade encapsulation services for targeted delivery of nucleic acid drugs to specific cells or tissues, empowering in vivo CAR and targeted gene editing therapies with a robust delivery tool.
•Robust conjugation processes ensure product homogeneity and process consistency
•High conjugation efficiency ensures effective targeted delivery of nucleic acid therapeutics
•Platform drug products have been validated for in vivo delivery in non-human primates (NHPs)
•Supports conjugation of full-length IgG, VHH nanobodies, scFvs, and other antibody formats
•Supports commercial lipids (e.g., SM102), Enorna proprietary, and customer-supplied novel lipids
•From 2 mL research-grade to 1000 mL GLP-grade manufacturing, with CDMO services capable of reaching gram-scale production
•Antibody Conjugation Efficiency
•Antibody Copy Number
•Empty LNP
1）Commercial lipids
2）Enorna-recommended novel lipids
3）Customer-supplied novel lipids
1）Commercial lipids
2）Enorna-recommended novel lipids
3）Customer-supplied novel lipids
a) RNA-tLNP
b) Report of Analysis (RoA)
a) RNA-tLNP
b) Report of Analysis (RoA)
For other custom requirements, please contact us for inquiries.
Contact us
<4k nt: ≥75%
>4k nt: Report value
MC3-LNP 80-110 nm
SM102-LNP 65-125 nm
LP01-LNP 65-125 nm
ALC0315-LNP 50-100 nm
Y
N
Optional
Enorna's NanoFCM platform offers comprehensive services, including sample analysis, analytical method development, and validation.
Particle Size
Size Distribution Profile
Size Standard Deviation
Absolute Concentration (Particles/mL)
Empty LNP
Free Nucleic Acid Ratio
Surface-Adsorbed Nucleic Acid Ratio
Nucleic Acid Copy Number
Encapsulation Efficiency
Antibody Conjugation Efficiency
Antibody Conjugation Copy Number
Full capabilities in analytical method development, validation, and transfer
User access control, electronic signatures, and audit trail functionality
Instruments undergo rigorous calibration and quality control to ensure all analyses are performed under controlled conditions
CD8 VHH nanobody-conjugated LNP analyzed using fluorescent antigen and fluorescence-quantified microspheres, demonstrating a conjugation density of ~42.1
CD8 VHH nanobody-conjugated LNP assessed with fluorescent antigen, achieving a conjugation efficiency of ~94%
Transmembrane nucleic acid dye was used to quantify empty LNPs/tLNPs, showing an empty rate of ~3.6%
Tel. +86 18961517608
E-mail. bd@enorna.com
Address.
63 Keji Avenue,
Bldg. 6, Fl. 6,
Yixing, Jiangsu, China
